is predicted to decrease the exposure to imatinib.

Study

▶ Nevirapine

r

is predicted to decrease the exposure to ivacaftor.

Theoretical

▶ Nevirapine is predicted to decrease the exposure to lapatinib.

Avoid.rStudy

▶ Nevirapine is predicted to decrease the efficacy of

levonorgestrel. For FSRH guidance, see Contraceptives,

interactions p. 794.rTheoretical

▶ Nevirapine is predicted to decrease the exposure to lurasidone.

Monitor and adjust dose.oTheoretical

▶ Nevirapine decreases the exposure to macrolides

(clarithromycin).oStudy

▶ Nevirapine decreases the concentration of midazolam. Monitor

and adjust dose.oStudy

▶ Mitotane

r

is predicted to decrease the exposure to nevirapine.

Theoretical

▶ Nevirapine

o

is predicted to decrease the exposure to netupitant.

Theoretical

▶ Nevirapine is predicted to decrease the exposure to nilotinib.

Avoid.rTheoretical

▶ Nevirapine is predicted to decrease the efficacy of

norethisterone. For FSRH guidance, see Contraceptives,

interactions p. 794.rAnecdotal

▶ Nevirapine is predicted to decrease the exposure to olaparib.

Avoid.oTheoretical

BNF 78 Neuromuscular blocking drugs, non-depolarising — Nevirapine 1501

Interactions | Appendix 1

A1

Nevirapine (continued)

▶ Nevirapine is predicted to decrease the exposure to ombitasvir.

Avoid.rTheoretical

▶ Nevirapine decreases the exposure to opioids (methadone).

Monitor and adjust dose.rStudy

▶ Nevirapine is predicted to decrease the exposure to

osimertinib.rTheoretical

▶ Nevirapine is predicted to decrease the exposure to

ospemifene.oStudy

▶ Nevirapine is predicted to decrease the exposure to

paritaprevir

Study

(with ritonavir and ombitasvir). Avoid.r

▶ Nevirapine is predicted to decrease the exposure to

phosphodiesterase type-5 inhibitors.oTheoretical

▶ Nevirapine is predicted to decrease the exposure to

pibrentasvir. Avoid.rStudy

▶ Nevirapine

o

is predicted to decrease the exposure to quetiapine.

Study

▶ Nevirapine

o

is predicted to decrease the exposure to ribociclib.

Study

▶ Rifampicin

r

decreases the concentration of nevirapine. Avoid.

Study

▶ Nevirapine is predicted to decrease the exposure to rilpivirine.

Avoid.rTheoretical

▶ Nevirapine is predicted to decrease the exposure to rolapitant.

Avoid.rStudy

▶ Nevirapine is predicted to decrease the exposure to ruxolitinib.

Monitor and adjust dose.oTheoretical

▶ Nevirapine is predicted to decrease the concentration of

sirolimus. Monitor and adjust dose.oTheoretical

▶ St John’s Wort is predicted to decrease the concentration of

nevirapine. Avoid.rTheoretical

▶ Nevirapine slightly decreases the exposure to statins

(atorvastatin).nStudy

▶ Nevirapine moderately decreases the exposure to statins

(simvastatin).oStudy

▶ Nevirapine is predicted to decrease the concentration of

tacrolimus. Monitor and adjust dose.oTheoretical

▶ Nevirapine is predicted to decrease the exposure to taxanes

(cabazitaxel). Avoid.rStudy

▶ Nevirapine is predicted to decrease the concentration of

temsirolimus. Avoid.rTheoretical

▶ Nevirapine

o

is predicted to decrease the exposure to ticagrelor.

Theoretical

▶ Nevirapine

o

is predicted to decrease the exposure to tofacitinib.

Study

▶ Nevirapine decreases the efficacy of ulipristal. For FSRH

guidance, see

Anecdotal

Contraceptives, interactions p. 794.r

▶ Nevirapine is predicted to decrease the exposure to velpatasvir.

Avoid.oTheoretical

▶ Nevirapine is predicted to decrease the exposure to venetoclax.

Avoid.rStudy

▶ Nevirapine is predicted to decrease the concentration of

voxilaprevir. Avoid.rTheoretical

▶ Nevirapine is predicted to decrease the concentration of

zidovudine. Refer to specialist literature.rTheoretical

Nicardipine → see calcium channel blockers

Nicorandil → see TABLE 8 p. 1376 (hypotension)

▶ Aspirin is predicted to increase the risk of gastrointestinal

perforation when given with nicorandil.rTheoretical

▶ Corticosteroids increase the risk of gastrointestinal

perforation when given with nicorandil.rAnecdotal

▶ Nicorandil is predicted to increase the risk of gastrointestinal

perforation when given with NSAIDs.rTheoretical

▶ Nicorandil is predicted to increase the risk of hypotension

when given with

r

phosphodiesterase type-5 inhibitors. Avoid.

Theoretical → Also see TABLE 8 p. 1376

Nicotinic acid → see TABLE 3 p. 1375 (anticoagulant effects)

▶ Nicotinic acid is predicted to increase the risk of

rhabdomyolysis when given with statins.rTheoretical

Nifedipine → see calcium channel blockers

Nilotinib → see TABLE 15 p. 1378 (myelosuppression), TABLE 9 p. 1377

(QT-interval prolongation)

▶ Nilotinib

o

is predicted to increase the exposure to abemaciclib.

Study

▶ Nilotinib is predicted to increase the exposure to aldosterone

Study

antagonists (eplerenone). Adjust eplerenone dose, p. 193.r

▶ Nilotinib is predicted to increase the exposure to alpha blockers

(tamsulosin).oTheoretical

▶ Nilotinib

r

is predicted to increase the exposure to alprazolam.

Study

▶ Antacids are predicted to decrease the absorption of nilotinib.

Separate administration by at least 2 hours.

Theoretical

o ▶ Nilotinib is predicted to increase the exposure to

o

antiarrhythmics (propafenone). Monitor and adjust dose.

Study

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to moderately decrease

the exposure to nilotinib. Avoid.rStudy

▶ Antifungals, azoles (fluconazole, posaconazole) are predicted to

increase the exposure to nilotinib.oTheoretical → Also

see TABLE 9 p. 1377

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to moderately increase the exposure to nilotinib.

Avoid.rStudy → Also see TABLE 9 p. 1377

▶ Nilotinib is predicted to increase the exposure to

antihistamines, non-sedating (mizolastine).rTheoretical

▶ Nilotinib is predicted to increase the exposure to

antihistamines, non-sedating (rupatadine). Avoid.oStudy

▶ Nilotinib is predicted to increase the concentration of

antimalarials (piperaquine).rTheoretical

▶ Aprepitant

o

is predicted to increase the exposure to nilotinib.

Theoretical

▶ Nilotinib

o

is predicted to increase the exposure to axitinib.

Theoretical → Also see TABLE 15 p. 1378

▶ Nilotinib is predicted to increase the exposure to bedaquiline.

Avoid prolonged use.nTheoretical → Also see TABLE 9 p. 1377

▶ Bosentan is predicted to decrease the exposure to nilotinib.

Avoid.rTheoretical

▶ Nilotinib is predicted to increase the exposure to bosutinib.

Avoid or adjust dose.rTheoretical → Also see TABLE 15

p. 1378 → Also see TABLE 9 p. 1377

▶ Nilotinib is predicted to increase the exposure to buspirone.

Use with caution and adjust dose.oStudy

▶ Nilotinib

o

is predicted to increase the exposure to cabozantinib.

Theoretical → Also see TABLE 15 p. 1378 → Also see TABLE 9

p. 1377

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the exposure to nilotinib.oTheoretical

▶ Nilotinib is predicted to increase the exposure to calcium

channel blockers (amlodipine, felodipine, lacidipine,

lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and

adjust dose.oStudy

▶ Nilotinib is predicted to increase the exposure to cariprazine.

Avoid.rStudy

▶ Nilotinib

o

is predicted to increase the exposure to ceritinib.

Theoretical → Also see TABLE 15 p. 1378 → Also see TABLE 9

p. 1377

▶ Nilotinib is predicted to increase the concentration of

ciclosporin.rStudy

▶ Cobicistat is predicted to moderately increase the exposure to

nilotinib. Avoid.rStudy

▶ Nilotinib

r

is predicted to increase the exposure to cobimetinib.

Theoretical

▶ Nilotinib is predicted to increase the exposure to colchicine.

Adjust colchicine dose with moderate inhibitors of CYP3A4,

p. 1120.rStudy

▶ Nilotinib is predicted to increase the exposure to corticosteroids

(methylprednisolone). Monitor and adjust dose.oStudy

▶ Nilotinib is predicted to increase the risk of bleeding events

when given with coumarins.rTheoretical

▶ Nilotinib is predicted to slightly increase the exposure to

darifenacin.oStudy

▶ Nilotinib

r

is predicted to increase the exposure to dasatinib.

Study → Also see TABLE 15 p. 1378 → Also see TABLE 9 p. 1377

1502 Nevirapine — Nilotinib BNF 78

Interactions | Appendix 1

A1

▶ Nilotinib increases the risk of QT-prolongation when given

with domperidone. Avoid.rStudy

▶ Nilotinib is predicted to increase the exposure to dopamine

receptor agonists (bromocriptine).rTheoretical

▶ Nilotinib is predicted to increase the concentration of

dopamine receptor agonists (cabergoline).oAnecdotal

▶ Nilotinib is predicted to moderately increase the exposure to

dutasteride.nStudy

▶ Efavirenz is predicted to decrease the exposure to nilotinib.

Avoid.rTheoretical → Also see TABLE 9 p. 1377

▶ Nilotinib is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Nilotinib is predicted to moderately increase the exposure to

encorafenib.oStudy → Also see TABLE 9 p. 1377

▶ Enzalutamide is predicted to moderately decrease the

exposure to nilotinib. Avoid.rStudy

▶ Nilotinib is predicted to increase the risk of ergotism when

given with ergometrine.rTheoretical

▶ Nilotinib is predicted to increase the risk of ergotism when

given with ergotamine.rTheoretical

▶ Nilotinib

o

is predicted to increase the exposure to erlotinib.

Theoretical

▶ Nilotinib is predicted to increase the concentration of

everolimus. Avoid or adjust dose.oStudy → Also see

TABLE 15 p. 1378

▶ Nilotinib is predicted to increase the exposure to fesoterodine.

Adjust fesoterodine dose with moderate inhibitors of CYP3A4

in hepatic and renal impairment, p. 777.nStudy

▶ Nilotinib

o

is predicted to increase the exposure to gefitinib.

Theoretical → Also see TABLE 15 p. 1378

▶ Grapefruit juice is predicted to increase the exposure to

nilotinib. Avoid.rTheoretical

▶ Nilotinib is predicted to increase the concentration of

guanfacine. Adjust guanfacine dose, p. 352.oTheoretical

▶ H2 receptor antagonists are predicted to decrease the

absorption of nilotinib. H2 receptor antagonists should be taken

10 hours before or 2 hours after nilotinib.nTheoretical

▶ HIV-protease inhibitors are predicted to moderately increase

the exposure to nilotinib. Avoid.rStudy → Also see TABLE 9

p. 1377

▶ Nilotinib is predicted to increase the exposure to ibrutinib.

Adjust ibrutinib dose with moderate inhibitors of CYP3A4,

p. 983.rStudy → Also see TABLE 15 p. 1378

▶ Idelalisib is predicted to moderately increase the exposure to

nilotinib. Avoid.rStudy → Also see TABLE 15 p. 1378

▶ Nilotinib is predicted to increase the exposure to ivabradine.

Adjust ivabradine dose, p. 211.rTheoretical

▶ Nilotinib is predicted to increase the exposure to ivacaftor.

Adjust ivacaftor p. 293 or tezacaftor with ivacaftor p. 295 dose

with moderate inhibitors of CYP3A4.rStudy

▶ Nilotinib

o

is predicted to increase the exposure to lapatinib.

Study → Also see TABLE 9 p. 1377

▶ Nilotinib is predicted to increase the exposure to lomitapide.

Avoid.oTheoretical

▶ Nilotinib is predicted to increase the exposure to lurasidone.

Adjust lurasidone dose, p. 398.oStudy

▶ Macrolides (clarithromycin) are predicted to moderately

increase the exposure to nilotinib. Avoid.rStudy → Also

see TABLE 9 p. 1377

▶ Macrolides (erythromycin) are predicted to increase the

exposure to nilotinib.oTheoretical → Also see TABLE 9

p. 1377

▶ Nilotinib is predicted to increase the exposure to midazolam.

Monitor side effects and adjust dose.rStudy

▶ Nilotinib

o

is predicted to increase the exposure to midostaurin.

Theoretical

▶ Mitotane is predicted to moderately decrease the exposure to

nilotinib. Avoid.rStudy → Also see TABLE 15 p. 1378

▶ Nilotinib is predicted to increase the exposure to naloxegol.

Adjust

Study

naloxegol dose and monitor side effects, p. 65.o ▶ Netupitant

o

is predicted to increase the exposure to nilotinib.

Theoretical

▶ Nevirapine is predicted to decrease the exposure to nilotinib.

Avoid.rTheoretical

▶ Nilotinib is predicted to increase the exposure to olaparib.

Avoid moderate inhibitors of CYP3A4 or adjust olaparib dose,

p. 1005.oTheoretical → Also see TABLE 15 p. 1378

▶ Nilotinib is predicted to increase the exposure to opioids

(alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and

adjust dose.oStudy

▶ Nilotinib is predicted to increase the exposure to opioids

(methadone, sufentanil).oTheoretical → Also see TABLE 9

p. 1377

▶ Nilotinib is predicted to increase the exposure to oxybutynin.

nTheoretical

▶ Nilotinib

o

is predicted to increase the exposure to pazopanib.

Theoretical → Also see TABLE 15 p. 1378 → Also see TABLE 9

p. 1377

▶ Nilotinib is predicted to increase the risk of bleeding events

when given with phenindione.rTheoretical

▶ Nilotinib is predicted to increase the exposure to

phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil

dose, p. 812.oTheoretical

▶ Nilotinib is predicted to increase the exposure to

phosphodiesterase type-5 inhibitors (sildenafil). Monitor or

adjust sildenafil dose with moderate inhibitors of CYP3A4,

p. 813.oStudy → Also see TABLE 9 p. 1377

▶ Nilotinib is predicted to increase the exposure to

phosphodiesterase type-5 inhibitors (tadalafil).rTheoretical

▶ Nilotinib is predicted to increase the exposure to

r

phosphodiesterase type-5 inhibitors (vardenafil). Adjust dose.

Theoretical → Also see TABLE 9 p. 1377

▶ Nilotinib is predicted to increase the exposure to pimozide.

Avoid.rTheoretical → Also see TABLE 9 p. 1377

▶ Pitolisant is predicted to decrease the exposure to nilotinib.

Avoid.rTheoretical

▶ Nilotinib is predicted to increase the exposure to quetiapine.

Avoid.oStudy

▶ Nilotinib

r

is predicted to increase the exposure to ranolazine.

Study → Also see TABLE 9 p. 1377

▶ Nilotinib

o

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more